[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-455994-105":59,"doc-detail-455994-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","soluble-guanylate-cyclase-modulators-a-novel-therapeutic-approach-for-diabetic-kidney-disease","Soluble guanylate cyclase modulators - a novel therapeutic approach for diabetic kidney disease","","Diabetic kidney disease (DKD) is a frequent diabetes complication affecting about 40% of patients and creating major health and economic burdens worldwide. Existing therapies show limited effectiveness as DKD prevalence rises. Soluble guanylate cyclase (sGC) modulators, including activators and stimulators, enhance cyclic guanosine monophosphate to drive vasodilatory, anti-inflammatory, and anti-fibrotic actions. Preclinical DKD models demonstrate improved renal function and reduced proteinuria, while early clinical data suggest renal protection and good tolerability; larger studies are needed to confirm long-term efficacy and safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/soluble-guanylate-cyclase-modulators-a-novel-therapeutic-approach-for-diabetic-kidney-disease/455994/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/soluble-guanylate-cyclase-modulators-a-novel-therapeutic-approach-for-diabetic-kidney-disease/455994.png","ImageObject",300,407,{"name":92,"@type":93},"Bintang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes diabetic kidney disease (DKD) clinically challenging?","Question",{"text":112,"@type":113},"DKD affects roughly 40% of patients with diabetes and imposes substantial health and economic burdens, while current treatments have limited efficacy in slowing progression.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How do sGC modulators work in DKD?",{"text":117,"@type":113},"sGC modulators increase cyclic guanosine monophosphate, producing vasodilatory, anti-inflammatory, and anti-fibrotic effects that help mitigate DKD-related pathology.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports sGC modulators for DKD?",{"text":121,"@type":113},"Preclinical studies show improved renal function and reduced proteinuria in DKD models, and early clinical findings with sGC activators like avenicguat suggest renal protection and good tolerability.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},455994,1790949775,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962085564381,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Renal FailuRe  \n2025, VOl. 47, nO. 1, 2595385  \n[https://doi.org/10.1080/0886022X.2025.2595385](https://doi.org/10.1080/0886022X.2025.2595385)  \nState of the art review    \nSoluble guanylate cyclase modulators—a novel therapeutic approach for diabetic kidney disease  \nYuqing Xua*, Xuan wua*, Mingpai Geb*, Kunhan Lianga*, Jixin Xinga, Peng Zhanga, huilin Lic, Zhiyong Guoa and Xiaobin Meia  \naDepartment of nephrology, Changhai Hospital, naval Medical university, Shanghai, China; bDepartment of Gastrointestinal Surgery, Changhai Hospital, naval Medical university, Shanghai, China; cDepartment of nephrology, Gongli Hospital of Shanghai Pudong new area, Shanghai, China  \nABSTRACT  \nDiabetic kidney disease (DKD) is a common complication, affecting approximately 40% of patients with diabetes and imposing substantial health and economic burdens [worldwide. as](worldwide. as) DKD prevalence rises, existing treatments remain limited in efficacy, necessitating innovative therapeutic strategies. Soluble guanylate cyclase (sGC) modulators, including activators and stimulators, have emerged as promising treatments by enhancing cyclic guanosine monophosphate production, thereby exerting vasodilatory, anti-inflammatory, and anti-fibrotic effects. Preclinical studies have demonstrated their efficacy in improving renal function and reducing proteinuria in DKD models. Notably, clinical trials involving sGC activators, such as avenicguat, suggest potential benefits in managing DKD, particularly in combination with renin-angiotensinaldosterone system inhibitors. while initial findings indicate renal protection and good tolerability, further large-scale studies are needed to confirm long-term efficacy and safety. the development of sGC modulators offers hope for improving DKD outcomesand reducing its global healthcare burden.  \nGRAPHICAL ABSTRACT  \nARTICLE HISTORY  \nreceived 13 april 2025 revised 18 July 2025 accepted 22 July 2025  \nKEYWORDS  \nsGC modulators; diabetic kidney disease;  \nproteinuria; efficacy; safety  \nCONTACT Zhiyong Guo  [drguozhiyong@163.com](drguozhiyong@163.com); Xiaobin Mei  meixiaobin168@163.com  Department of nephrology, Changhai Hospital, naval Medical university, 168 Changhai Road, Yangpu District, Shanghai, China.  \n*Contributed equally to this work.  \n© 2026 The author(s) . Published by informa uK limited, trading as Taylor & Francis Group.  \nThis is an Open access article distributed under the terms of the Creative Commons attribution license ([http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the accepted Manuscript in a repository by the author(s) or with their consent.  \n2  Y. XU et aL.  \nGraphical abstract illustrating the pathological mechanisms and therapeutic potential of soluble guanylate cyclase (sGC) modulators in diabetic kidney disease (DKD). the top left panel depicts the pathological environment of DKD, featuring hyperglycemia, increased production of reactive oxygen species (roS), oxidative stress, and nitric oxide (No) deficiency. the top right panel outlines the classification of sGC modulators into No-independent activators and No-synergistic stimulators. the bottom left panel summarizes the core therapeutic effects of sGC modulation, including anti-fibrotic (tGf-β), anti-inflammatory (Nf-κB), vasodilatory (cGMP), and antioxidant (roS) actions. the bottom right panel highlights clinical benefits associated with sGC modulators, such as estimated glomerular filtration rate (eGfr) stabilization, delayed chronic kidney disease (CKD) progression, and a reduction in urinary albumin-to-creatinine ratio (UaCr) by approximately 45%, collectively contributing to improved renal outcomes in DKD.  \n1. Introduction  \naccording to the international Diabetes federation, in 2021, the gl","cbCailCfzlNTvNWu","https://ap.wps.com/l/cbCailCfzlNTvNWu","pdf",1178174,15,"English","# Introduction\n## NO–sGC–cGMP signaling pathway in DKD\n# Pathophysiology of the NO–sGC–cGMP","[{\"question\":\"What makes diabetic kidney disease (DKD) clinically challenging?\",\"answer\":\"DKD affects roughly 40% of patients with diabetes and imposes substantial health and economic burdens, while current treatments have limited efficacy in slowing progression.\"},{\"question\":\"How do sGC modulators work in DKD?\",\"answer\":\"sGC modulators increase cyclic guanosine monophosphate, producing vasodilatory, anti-inflammatory, and anti-fibrotic effects that help mitigate DKD-related pathology.\"},{\"question\":\"What evidence supports sGC modulators for DKD?\",\"answer\":\"Preclinical studies show improved renal function and reduced proteinuria in DKD models, and early clinical findings with sGC activators like avenicguat suggest renal protection and good tolerability.\"}]","Soluble guanylate cyclase modulators - a novel therapeutic approach for diabetic kidney disease | PDF",1790744879,38]